Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceGlobeNewsWire · Oct 13, 2026
Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)Defense World · Sep 30, 2026
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewsWire · Sep 1, 2026
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · Aug 25, 2026
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks TranscriptSeeking Alpha · Aug 20, 2026
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research · Aug 10, 2026Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.55 | -$0.73 | Miss |
| May 11, 2026 | -$0.60 | -$0.61 | Miss |
| Mar 5, 2026 | -$0.58 | -$0.60 | Miss |
| Nov 11, 2025 | -$0.60 | -$0.55 | Beat |
| Aug 12, 2025 | -$0.68 | -$0.54 | Beat |
| May 13, 2025 | -$0.62 | -$0.68 | Miss |